FN2 Earnings Intelligence

Neurocrine Biosciences, Inc. earnings overview

Latest Neurocrine Biosciences, Inc. (NBIX) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.

Next reportNeurocrine Biosciences, Inc. reports Wednesday, Feb 10, 2027 · After market closeConsensus EPS $2.73 · consensus revenue $1.08B
NBIX FY2026 Q3 · Calendar Q4 2026

Neurocrine Biosciences, Inc.

The quarter supports a growth thesis built on momentum across INGREZZA, CRENESITY and VYKAT XR, with a higher INGREZZA outlook and multiple pipeline programs advancing. The thesis remains exposed to pricing pressure, VYKAT XR safety and persistence questions, and the uncertainty inherent in clinical development.

EPS surprise+72.3%
Market move-0.5%

Get the NBIX recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.